Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis stalwart Peter Maag to head up XDx

This article was originally published in Clinica

Executive Summary

Molecular diagnostics firm XDx has appointed Peter Maag president and CEO as it seeks to accelerate sales and expand its geographic reach. Dr Maag previously worked for Novartis since 2001, most recently as president of Novartis Diagnostics, a position he held since 2009. Brisbane, California-based XDx's lead product is the AlloMap gene expression blood test, which is used to monitor heart transplant recipients, to help predict if a patient will reject their transplanted organ. The test was cleared by the FDA in 2008. In May this year, XDx signed an agreement with LabCorp to co-develop and commercialise a diagnostic test to predict flares of systemic lupus erythematosus. More recently, XDx has closed a $15 million senior credit facility.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel